| Iupac Name: | (2R)-2-[3-({1,3-Benzoxazol-2-yl[3-(4-methoxyphenoxy)propyl]amino}methyl)phenoxy]butanoic acid |
| Tradename: | Parmodia |
| Routes Of Administration: | Oral |
| Atc Prefix: | C10 |
| Atc Suffix: | AB12 |
| Legal Status: | Rx-only |
| Cas Number: | 848259-27-8 |
| Chemspiderid: | 9700824 |
| Unii: | 17VGG92R23 |
| Kegg: | D10711 |
| Chebi: | 228365 |
| Chembl: | 247951 |
| Synonyms: | K-13675 |
| C: | 28 |
| H: | 30 |
| N: | 2 |
| O: | 6 |
| Smiles: | CC[C@H](C(=O)O)Oc1cccc(c1)CN(CCCOc2ccc(cc2)OC)c3nc4ccccc4o3 |
| Stdinchi: | 1S/C28H30N2O6/c1-3-25(27(31)32)35-23-9-6-8-20(18-23)19-30(28-29-24-10-4-5-11-26(24)36-28)16-7-17-34-22-14-12-21(33-2)13-15-22/h4-6,8-15,18,25H,3,7,16-17,19H2,1-2H3,(H,31,32)/t25-/m1/s1 |
| Stdinchikey: | ZHKNLJLMDFQVHJ-RUZDIDTESA-N |
Pemafibrate, sold under the brand namd Parmodia, is a peroxisome proliferator-activated receptor alpha (PPARα) agonist. It is developed and marketed by Kowa Pharmaceuticals.[1]
In July 2017, Pharmaceuticals and Medical Devices Agency approved it in Japan.[2]